You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

JAK/STAT inhibitors

Showing 1 - 25 of 4,598
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Rheumatoid Arthritis Trial ("apigenin" and "glycyrrhizin", "glycyrrhizin" and "boswellic acid", "")

Not yet recruiting
  • Rheumatoid Arthritis
  • "apigenin" and "glycyrrhizin"
  • +2 more
  • (no location specified)
Mar 27, 2023

Rheumatoid Arthritis Trial in Montpellier (Blood sample analysis of patients treated as standard care)

Recruiting
  • Rheumatoid Arthritis
  • Blood sample analysis of patients treated as standard care
  • Montpellier, France
    University Hospital of Montpellier
Jan 12, 2022

Kohlmeier Degos Disease With Neurologic Involvement Trial run by the National Heart, Lung, and Blood Institute (NHLBI)

Recruiting
  • Kohlmeier Degos Disease With Neurologic Involvement
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 23, 2023

JAK/STAT Pathway in Sarcoidosis Granuloma Cells

Recruiting
  • Sarcoidosis
  • JAK-STAT Pathway Deregulation
  • Blood sample
  • Bobigny, France
    Service de pneumologie Hôpital Avicenne
Oct 3, 2022

Synovial and Adipose Tissue Composition in Overweight/Obese

Active, not recruiting
  • Rheumatoid Arthritis
  • Assessment of synovial- and adipose tissue-derived inflammatory biomarkers
  • Rome, Italy
    Division of Rheumatology
Mar 2, 2023

JAK-STAT Signaling Pathway in Pyoderma Gangrenosum

Not yet recruiting
  • Pyoderma Gangrenosum
  • +2 more
  • immunohistochemical methods
  • (no location specified)
Mar 21, 2022

Toxic Epidermal Necrolysis Trial in Fuzhou (Abrocitinib)

Recruiting
  • Toxic Epidermal Necrolysis
  • Fuzhou, Fujian, China
    Department of Dermatology, the First Affiliated Hospital of Fuji
Oct 31, 2023

Diabetes, Type 1 Trial (Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo)

Not yet recruiting
  • Diabetes Mellitus, Type 1
  • Abrocitinib 200 MG Oral Tablet
  • +2 more
  • (no location specified)
Feb 21, 2023

Janus Kinase Inhibitors Vs Tumor Necrosis Factor Inhibitors in

Not yet recruiting
  • Rheumatoid Arthritis
  • Observation
  • (no location specified)
Oct 8, 2022

JAK Inhibition in Ulcerative Colitis

Not yet recruiting
  • Analyzing Immune Composition Changes Upon JAK Inhibitor Treatment of Ulcerative Colitis Patients
  • JAK inhibitor treatment
  • (no location specified)
Jul 11, 2022

JAK Inhibitors in Systemic Sclerosis-associated Interstitial

Recruiting
  • Systemic Sclerosis
  • Interstitial Lung Disease
    • Vandœuvre-lès-Nancy, Grand Est, France
      CHU Nancy
    Jan 19, 2022

    Rheumatoid Arthritis, Drug Use Trial in Hong Kong (biologic/targeted therapy)

    Not yet recruiting
    • Rheumatoid Arthritis
    • Drug Use
    • biologic/targeted therapy
    • Hong Kong, China
      Department of Medicine, Tuen Mun Hospital
    Jan 5, 2022

    Myelofibrosis Trial in Paris (Ruxolotinib)

    Completed
    • Myelofibrosis
    • Paris, France
      ROBIN
    Jul 26, 2022

    Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.

    Recruiting
    • Arthritis, Rheumatoid
      • Sevilla, Spain
        Hospital Universitario Virgen macarena
      Nov 15, 2021

      Inpatient COVID-19 Treatments

      Active, not recruiting
      • COVID-19
      • Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)
      • New York, New York
        Aetion, Inc.
      Jan 12, 2023

      COVID 19, Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors Trial

      Withdrawn
      • COVID 19
      • Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors
      • (no location specified)
      Sep 8, 2021

      Rheumatoid Arthritis, Inflammatory Rheumatism, Psoriatic Arthritis Trial in France (no intervention)

      Recruiting
      • Rheumatoid Arthritis
      • +3 more
      • no intervention
      • Antibes, France
      • +59 more
      Oct 25, 2022

      Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis

      Enrolling by invitation
      • Dermatitis, Atopic
        • Lisle-sur-Tarn, France
          Hop Claude Huriez Chu Lille
        May 27, 2021

        Head and Neck Squamous Cell Carcinoma Trial in Tucson, San Francisco (Ruxolitinib)

        Recruiting
        • Head and Neck Squamous Cell Carcinoma
        • Tucson, Arizona
        • +1 more
        Sep 22, 2022

        Rheumatoid Arthritis Trial in Montpellier (Ultrasound)

        Recruiting
        • Rheumatoid Arthritis
        • Ultrasound
        • Montpellier, France
          Rheumatology Department, Lapeyronie Hospital
        Jul 7, 2021

        Immunoclassification, Psoriasis Trial in Hangzhou (adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors,

        Recruiting
        • Immunoclassification
        • Psoriasis
        • adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate
        • Hangzhou, Zhejiang, China
          2nd Affiliated Hospital, School of Medicine, Zhejiang University
        Aug 16, 2022

        Systemic Sclerosis and Jak Inhibitors : Emphasis on Macrophages

        Recruiting
        • Systemic Sclerosis
        • biological analysis
        • Rennes, France
          Rennes University Hospital
        Mar 17, 2021

        Arthritis, Rheumatoid, Arthritis, Psoriatic, Spondyloarthritis Trial in Caba, Ciudad Autonoma Buenos Aires (DMARDs, biologic

        Recruiting
        • Arthritis, Rheumatoid
        • +2 more
        • Caba, Buenos Aires, Argentina
        • +1 more
        Mar 26, 2021

        Rheumatoid Arthritis Patients Treated With JAK-inhibitor

        Recruiting
        • Rheumatoid Arthritis
        • Upadacitinib <15 MG [Rinvoq]
        • Montpellier, France
          CHU de Montpellier
        Jan 12, 2022

        Vitiligo, Generalized Trial (Baricitinib)

        Not yet recruiting
        • Vitiligo, Generalized
        • (no location specified)
        Jul 7, 2023